MedTrace Logo

Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects

NCT05046808 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-06-08

No results posted yet for this study

Summary

This is a single-center, randomized, open-label study to compare the pharmacokinetic profiles of Famitinib and its metabolite SHR116637 at different doses/specifications.

Conditions

Interventions

DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 10mg single dose

DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 15mg single dose

DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 20mg single dose

DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 10mg\*2 single dose

DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 25mg single dose

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-23
Primary Completion
2021-10-08
Completion
2021-11-22

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05046808 on ClinicalTrials.gov